Bhubaneswar: The 7th National Conference of the Indian Society for the Study of Lung Cancer (ISSLC) has been held in the city. The theme of NALCCON 2016 “Lung Cancer-Multi-modality Approach for Better Survival” captured the collaborative spirit of the Conference which will be a scientific and educational event covering three major topics for active prevention, accurate diagnosis and advanced care of lung cancer. Near 300 experts in the field from all over country participated in this conference to exchange their knowledge and technical skill.Scientists, health professionals, government officials, partners from the industry, health advocacy groups and patients have come together in order to obtain and exchange information on both state-of-the-art and advances in the management of lung cancer and other thoracic malignancies, considering both national and regional aspects.
Lung cancer is a leading cause of death globally. The most commonly diagnosed cancers worldwide were those of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), and colorectum (1.4 million, 9.7%). The most common causes of cancer death were cancers of the lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%).
Projections based on the GLOBOCAN 2012 estimates predict a substantive increase to 19.3 million new cancer cases per year by 2025, due to growth and ageing of the global population.
It is also a major healthcare problem in India. The population based cancer registry of Indian Cancer Society from Maharashtra, which covers Mumbai, Pune, Nagpur and Aurangabad. In Odisha, there is no population based cancer registry to document the incidence of this fatal disease.But in clinical practice it is one of the leading cause of death in cancer related death. By extrapolating this data to the 1.16 billion Indians, at a national level this would translate into 235,104 new patients. With 90% of these presenting in an advanced inoperable stage, the future looks extremely challenging.
Hence we need to take advantage of technology like endobronchial ultrasound, PET and CT, mutation analysis appropriate staging and targeted treatment. These approaches have the potential to improve outcome in such patients using the personalised medicine approach.
Over the last 10 years the survival in lung cancer has increased from a median overall survival of 11 months to an overall 5-year survival rate of 17.8%. This benefit is mainly due to the availability of targeted therapy drugs and the appropriate selection of the patients – in other words precision oncology and personalised medicine.
The AIIMS , Bhubaneswar is committed to improvise the health care delivery system and improve teaching, research and patient care in this region of the country. This scientific event is being organised by the faculties Prof.MadhabanandaKar , Head of Surgical Oncology, Prof PrasantR.Mohapatra , head of Pulmonary medicine , Dr.Saroj Kumar Das Majumdar , From Radiation-oncology and patronised by the Medical Superintendent, Prof.Dillip K Parida, Dean , Prof.Vikas Bhatia, and Prof.GitanjaliBatmanabane , the director of AIIMS, Bhubaneswar, Odisha.